X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
to2 (101) 101
humans (92) 92
oncology (91) 91
original reports (75) 75
female (65) 65
middle aged (56) 56
aged (51) 51
male (48) 48
adult (34) 34
treatment outcome (34) 34
prognosis (30) 30
disease-free survival (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
aged, 80 and over (17) 17
mutation (17) 17
neoplasm staging (17) 17
to4 (17) 17
bios4 (16) 16
expression (16) 16
risk factors (16) 16
bc8 (15) 15
survival analysis (15) 15
bios3 (14) 14
to14 (14) 14
chemotherapy (13) 13
predictive value of tests (13) 13
proportional hazards models (13) 13
risk assessment (13) 13
breast neoplasms - drug therapy (12) 12
immunohistochemistry (12) 12
survival (12) 12
disease progression (11) 11
chemotherapy, adjuvant (10) 10
time factors (10) 10
to15 (10) 10
biomarkers, tumor - analysis (9) 9
breast neoplasms - pathology (9) 9
kaplan-meier estimate (9) 9
prospective studies (9) 9
thor12 (9) 9
to20 (9) 9
to5 (9) 9
young adult (9) 9
adolescent (8) 8
antineoplastic agents - therapeutic use (8) 8
bc2 (8) 8
biomarkers, tumor - blood (8) 8
cancer (8) 8
colorectal-cancer (8) 8
gene expression profiling (8) 8
genetic predisposition to disease (8) 8
neoplasms - drug therapy (8) 8
randomized controlled trials as topic (8) 8
retrospective studies (8) 8
to11 (8) 8
breast neoplasms - chemistry (7) 7
cohort studies (7) 7
gene expression regulation, neoplastic (7) 7
gic7 (7) 7
lung neoplasms - drug therapy (7) 7
lung neoplasms - pathology (7) 7
proto-oncogene proteins b-raf - genetics (7) 7
quinazolines - administration & dosage (7) 7
reproducibility of results (7) 7
to8 (7) 7
activation (6) 6
animals (6) 6
bc5 (6) 6
bevacizumab (6) 6
biomarkers, tumor - genetics (6) 6
biomarkers, tumor - metabolism (6) 6
biopsy (6) 6
breast neoplasms - genetics (6) 6
breast neoplasms - mortality (6) 6
breast-cancer (6) 6
cells (6) 6
hema9 (6) 6
lung neoplasms - blood (6) 6
lung neoplasms - genetics (6) 6
neoplasms - genetics (6) 6
to19 (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
bc7 (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
cell lung-cancer (5) 5
class i phosphatidylinositol 3-kinases (5) 5
early detection of cancer - methods (5) 5
faze (5) 5
gene (5) 5
gene amplification (5) 5
growth-factor receptor (5) 5
marker (5) 5
neoplasms - pathology (5) 5
neur8 (5) 5
phenotype (5) 5
phosphatidylinositol 3-kinases - genetics (5) 5
progesterone-receptor (5) 5
prostatic neoplasms - pathology (5) 5
receptors, estrogen - analysis (5) 5
recurrence (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 2, pp. 151 - 157
Adipokines are linked to obesity and insulin sensitivity and have recently been related to breast cancer risk and prognosis. We investigated the associations... 
Original Reports | To2 | Epid5
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 17, pp. 2205 - 2218
For almost four decades, my work has focused on one challenge: improving the delivery and efficacy of anticancer therapeutics. Working on the hypothesis that... 
INTERSTITIAL FLUID PRESSURE | VASCULAR NORMALIZATION | ANTIANGIOGENIC THERAPY | ONCOLOGY | PHASE-I TRIAL | NITRIC-OXIDE | FACTOR RECEPTOR-2 BLOCKADE | BLOOD-FLOW | ANTI-VEGF THERAPY | LYMPHATIC METASTASIS | ENDOTHELIAL GROWTH-FACTOR | Animals | Humans | Tumor Microenvironment | Neoplasms - blood supply | Molecular Medicine | Neoplasms - pathology | Neoplasms - drug therapy | Special | To6 | To5 | To7 | To2 | To1
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 31, pp. 5287 - 5297
The matrix metalloproteinase (MMP) family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been... 
ONCOLOGY | POOR-PROGNOSIS | COLORECTAL-CANCER | PROSTATE-CANCER | MATRIX-METALLOPROTEINASE-9 MMP-9 | MECHANISM-BASED INHIBITOR | TISSUE INHIBITOR | NECROSIS-FACTOR-ALPHA | GROWTH-FACTOR | TUMOR-GROWTH | STRUCTURE-BASED DESIGN | Biomarkers, Tumor - metabolism | Neoplasms - enzymology | Matrix Metalloproteinases - metabolism | Humans | Biology of Neoplasia | To2
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 32, pp. 3817 - 3825
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2016, Volume 34, Issue 10, pp. 1134 - 1150
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 24, pp. 4027 - 4034
Purpose Biomarkers can add substantial value to current medical practice by providing an integrated approach to prediction using the genetic makeup of the... 
ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | LUNG-CANCER | SURVIVAL BENEFIT | ONCOLOGY | PHASE-III | RECURRENCE | GENE COPY NUMBER | EXPRESSION | SIGNATURE | GEFITINIB IRESSA | Clinical Trials as Topic | Retrospective Studies | Prospective Studies | Biomarkers, Tumor | Research Design | Humans | To2 | Bios3 | Statistics in Oncology
Journal Article